| Name | Title | Contact Details |
|---|
MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.
Singular Genomics is pushing sequencing further to bring fast, powerful and flexible tools for research and medicine. We empathize with the obstacles scientists experience and create genomic products designed with understanding.
Pulmotect has developed PUL-042, an inhaled therapeutic which aims to boost the body`s innate immune system resulting in highly-targeted lung protection against all major classes of pathogens including bacteria, fungi, and viral pathogens.
Octapharma is committed to promoting excellence in patient care and providing valuable information to the medical and patient community. This will help to better manage the treatment of disease and to improve patient safety and population health
Takeda Oncology,, is a biopharmaceutical company based in Cambridge, Massachusetts.